Scarica l'app Stockscreener
26.45
1.12%
-0.30
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ROIV Giù?
Forum
Previsione
Roivant Sciences Ltd Borsa (ROIV) Ultime notizie
Roivant Sciences Advances PH Programs As Investors Weigh Pipeline Milestones - simplywall.st
Citi Raises Roivant Sciences (ROIV) PT to $35 Following Positive Phase 2 Brepocitinib Data - Insider Monkey
Insider Selling: Roivant Sciences (NASDAQ:ROIV) Director Sells 375,784 Shares of Stock - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Director Daniel Allen Gold Sells 425,000 Shares - MarketBeat
Healthcare REIT Posts 16.4% NOI Growth as Shares Soar 93%: Why This Fund's New Stake Stands Out - The Motley Fool
HC Wainwright Analysts Increase Earnings Estimates for ROIV - MarketBeat
Is Roivant Sciences Ltd. stock undervalued right now2025 Short Interest & AI Based Buy and Sell Signals - mfd.ru
Can Roivant Sciences Ltd. lead its sector in growthLayoff News & Detailed Earnings Play Alerts - mfd.ru
EV Market: What is IROQs debt to equity ratioJuly 2025 Snapshot & Verified Momentum Stock Watchlist - baoquankhu1.vn
Roivant Sciences (NASDAQ:ROIV) Insider Sells $8,985,003.27 in Stock - MarketBeat
Impax Asset Management Group plc Sells 200,000 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Why Roivant Sciences Ltd. (87S) stock appeals to dividend investors2025 Performance Recap & Expert Curated Trade Ideas - mfd.ru
Candriam S.C.A. Increases Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences stock price target raised to $33 from $26 at H.C. Wainwright - Investing.com Australia
TD Cowen Remains Bullish on Roivant Sciences Ltd. (ROIV)Here's Why - Finviz
Citi raises Roivant Sciences stock price target to $35 from $26 - Investing.com Australia
Citi raises Roivant Sciences stock price target to $35 from $26 By Investing.com - Investing.com South Africa
Roivant Sciences stock price target raised to $38 from $36 at Goldman Sachs By Investing.com - Investing.com South Africa
Roivant Sciences stock price target raised to $38 from $36 at Goldman Sachs - Investing.com India
TD Cowen Remains Bullish on Roivant Sciences Ltd. (ROIV) – Here’s Why - Insider Monkey
Roivant Sciences Earnings Call Highlights Brepocitinib Surge - TipRanks
Roivant Sciences stock hits all-time high at 26.35 USD By Investing.com - Investing.com Nigeria
Deep Dive Into Roivant Sciences Stock: Analyst Perspectives (4 Ratings) - Benzinga
Roivant Sciences stock hits all-time high at 26.35 USD - Investing.com
Roivant signals multiple pivotal trial readouts and accelerates brepocitinib phase III launch in 2026 - MSN
Roivant Sciences (ROIV) Valuation Check After Strong Share Price Momentum - Yahoo Finance
Looking At The Narrative For Roivant Sciences ROIV After 2026 Catalyst And Litigation Shifts - Yahoo Finance
Roivant Sciences stock rockets after brepocitinib Phase 2 win — what ROIV investors watch next - TechStock²
Lumentum, Woodward, And Teradyne Are Among the Top 10 Large-Cap Gainers Last Week (Feb. 2-Feb. 6): Are the Others in Your Portfolio?Lumentum Holdings (NASDAQ:LITE), Oshkosh (NYSE:OSK), Roivant Sciences (NASDAQ:ROIV), Regal Rexnord (N - Benzinga
Roivant Sciences Ltd. $ROIV Shares Bought by New York State Common Retirement Fund - MarketBeat
Roivant Sciences (ROIV) Q3 Loss Of US$265.9 Million Tests Bullish Profitability Narrative - simplywall.st
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday - TechStock²
Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2025 Earnings Call Transcript - Insider Monkey
Roivant Sciences (ROIV) Soars 19.4% as Pipeline Drugs Progress - Finviz
Roivant Sciences earnings missed by $0.07, revenue fell short of estimates - Investing.com South Africa
10 Easy Double-Digit Gainers - Insider Monkey
Roivant Sciences Q3 2026 Earnings Call Transcript - MarketBeat
Decoding Roivant Sciences Ltd (ROIV): A Strategic SWOT Insight - GuruFocus
Roivant: The Next Telavant Has Arrived With Brepocitinib's Blockbuster Data (Rating Upgrade) - Seeking Alpha
Roivant Sciences Q4 2025 slides: positive brepocitinib data drives pipeline momentum - Investing.com Nigeria
Roivant Sciences (ROIV) Is Up 19.4% After Advancing Phase 2 Pipeline Despite Wider Quarterly Loss - simplywall.st
Roivant Sciences Ltd (ROIV) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... By GuruFocus - Investing.com Canada
Earnings call transcript: Roivant Sciences misses Q3 2026 estimates despite stock surge - Investing.com Canada
Why Is Roivant Stock Trading Higher Today?Roivant Sciences (NASDAQ:ROIV) - Benzinga
Roivant Sciences (NASDAQ:ROIV) Reaches New 1-Year HighStill a Buy? - MarketBeat
Roivant Sciences Q3 Earnings Call Highlights - MarketBeat
Immunovant Q3 Earnings Call Highlights - Yahoo Finance
ROIV: Strong phase II data for brepocitinib in cutaneous sarcoidosis; multiple pivotal readouts ahead - TradingView
Roivant Sciences Q4 2025 slides: positive brepocitinib data drives pipeline momentum By Investing.com - Investing.com South Africa
Roivant Sciences Stock Rises 17% Over Positive Data From Phase 2 Study Of Brepocitinib - Nasdaq
Roivant Sciences stock soars after positive cutaneous sarcoidosis trial data By Investing.com - Investing.com Australia
Pfizer-backed Priovant posts positive data for lead asset (PFE) - Seeking Alpha
Roivant Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 - marketscreener.com
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Priovant announces positive phase 2 results for brepocitinib in cutaneous sarcoidosis (Cs) - marketscreener.com
Roivant Sciences Ltd. SEC 10-Q Report - TradingView
0.87%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):